|
| Press Releases |
|
 |
|
| Wednesday, September 6, 2017 |
|
|
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma |
| The decision to expand the target number of enrolled patients is based on favourable interim analysis results of the endometrial cohort in a Phase Ib/II study (Study 111) of lenvatinib in combination with pembrolizumab for multiple solid cancers, which is being jointly conducted by Eisai and Merck & Co., Inc. more info >> |
|
| Friday, September 1, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017. more info >> |
|
| Thursday, July 27, 2017 |
|
|
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
| Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. more info >> |
|
| Wednesday, July 26, 2017 |
|
|
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma |
| Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). more info >> |
|
| Tuesday, July 4, 2017 |
|
|
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems |
| Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related problems, such as dementia, and extending healthy life expectancy. more info >> |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans 
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 9, 2026 14:24 JST
|
|
|
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 9, 2026 13:27 JST
|
|
|
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 9, 2026 13:05 JST
|
|
|
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 9, 2026 10:23 JST
|
|
|
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 9, 2026 10:07 JST
|
|
|
Capital Margin Trade Announces the Launch of Practical Trading Tools Designed For Structured Market Execution
Jan 9, 2026 07:00 HKT/SGT
|
|
|
Military Metals Announces Buyback of 1% Royalty on Slovakian Portfolio
Jan 8, 2026 20:59 HKT/SGT
|
|
|
Hong Kong Tech Firms Win Big at CES 2026 with Frontier Tech Innovations to Draw Global Buyer Interest
Jan 8, 2026 19:31 HKT/SGT
|
|
|
Education & Careers Expo opens 22 January
Jan 8, 2026 16:29 HKT/SGT
|
|
|
Hall Chadwick to Convene Invitation-Only Capital Access Forum for APAC Corporates Exploring Global Capital Pathways
Jan 8, 2026 14:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
